Official UK procurement notice
Aseptically Prepared Systemic Anti-Cancer Therapy Medicines
Authority: Mid and South Essex NHS Foundation Trust (Central government)·On behalf of: HealthTrust Europe LLP
What is being bought4 lots · detail below
Published requirement descriptionThis framework agreement is for the supply of a range of aseptically prepared, batch manufactured systemic anti-cancer therapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific systemic anti-cancer therapy drugs and medicines used in CIVAs.
CPV: Pharmaceutical products
How this framework works
From the published notice- Type
- Closed framework · open framework scheme (admission reopens)
- Call-offs
- call-offs may be awarded directly or by further competition
- Bids received
- 6 bids on the busiest of 4 lots · 6 suppliers appointed
- Framework period
- 8 yrs from 1 Sept 2026
- Scheme runs until
- 30 Aug 2034
- Supplier levy on call-offs (max %)
- 2% of call-off value
Published description of the framework
Suppliers will be ranked based on their technical and commercial scores at award stage of this Framework.
Call Off contracts will then be awarded via Direct Award or through further mini-competition with awarded suppliers under the applicable Lots. Specific technical and/or commercial elements will be awarded, scored and fed back on for all suppliers at framework award stage. Due to the nature of these goods and services, they may align to a customers requirements in these areas. These requirements and offerings will be differentiators at any call off stage, as well as any specific technical or commercial requirements presented by suppliers on the public sector landscape.
Lots and requirements (4)Procurement structure
4 lots · all with a published value · same conditions of participation on every lot · same evaluation weights on every lotEvery one of these 4 lots carries the same published figure, £850,000,000: it is the framework's maximum for the whole notice, not each lot's own budget, and no share per lot is published. The cards below say ceiling above rather than repeat it.
Lot #1Dose Banded Systemic Anti-Cancer Therapy MedicinesAwarded UK, East Midlands +2ceiling above
The source published no individual description for this lot.
- Economic & financial standing
As per "ITT Guidance - Aseptically Prepared Systemic Anti-Cancer Therapy Medicines" and PSQ requirements.
Lot #2Patient Specific Systemic Anti-Cancer Therapy MedicinesAwarded East Midlands, West Midlands +1ceiling above
The source published no individual description for this lot.
- Economic & financial standing
As per "ITT Guidance - Aseptically Prepared Systemic Anti-Cancer Therapy Medicines" and PSQ requirements.
Lot #3CIVAS (Central Intravenous Additive Service)Awarded East Midlands, West Midlands +1ceiling above
The source published no individual description for this lot.
- Economic & financial standing
As per "ITT Guidance - Aseptically Prepared Systemic Anti-Cancer Therapy Medicines" and PSQ requirements.
Lot #4Stock Inventory Management and Supply of Compounded Systemic Anti-Cancer Therapy MedicinesAwarded East Midlands, West Midlands +1ceiling above
The source published no individual description for this lot.
- Economic & financial standing
As per "ITT Guidance - Aseptically Prepared Systemic Anti-Cancer Therapy Medicines" and PSQ requirements.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published sub-criteria (2)
- Technical (Including Social Value): 65%
- Cost: 35%
Published award criteria (2)
- Technical (Including Social Value)
- Cost
- Economic & financial standing
As per "ITT Guidance - Aseptically Prepared Systemic Anti-Cancer Therapy Medicines" and PSQ requirements.
- Price carries 35 of 100 points: a 10% discount moves about 3.5 points. The method statement decides this lot, not the discount.
- “Aseptically Prepared Systemic Anti-Cancer Therapy Medicines” is a framework: the contest is a place on its panel, not a single contract: call-offs may be direct or by further competition.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record- Procedure method
- Open procedure
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Above threshold (FTS publication)
- Regulatory regime
- Standard
- Commercial structure
- Open framework scheme
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 22 May 2025, 10:24 BST
- Last source update
- 26 Oct 2026, 12:28 GMT
- Award evaluation window
- Submission end – 23 Jun 2026
- Authority reference
PR-2264- FTS notice number
2026/S 000-033144- Latest notice
- Contract award notice (UK6)
- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-051cdeFind a Tender
How it was run
Official notice- Appointment period ends
- 11 May 2026, 15:00 BST
- Clarification deadline
- 1 May 2026, 17:00 BST
- Submission channel
- Official e-sourcing portal
- Electronic submission
- Allowed
- Accepted languages
- en
- Supplier levy on call-offs (max %)
- call-off levy · 2% of call-off value
Via the Bravo Solutions Portal ONLY - healthtrusteurope.bravosolution.co.uk/web/login.shtml ↗
Timeline
22 May 2025 → 4 Nov 2026 · 11 dates- Planning notice published22 May 2025, 10:24 BST
- Market engagement361 days ago31 Oct 2025, 23:59 GMT
Engagement will be conducted through meetings/in-person discussions/telephone discussions with potential primary providers who can supply Aseptically Prepared Dose Banded Medicines. The engagement excersise aims to establish the following:
a. developing the authority’s requirements and approach to the procurement;
b. designing the award criteria;
c. preparing the tender notice and associated tender documents;
d. identifying suppliers that may be able to supply the goods required;
e. identifying likely contractual terms
Interested parties, please reach out to Neli Raleva neli.raleva@htepg.com to schedule a meeting.
- Next notice expected288 days ago12 Jan 2026, 23:59 GMT
- Tender notice published198 days ago13 Apr 2026, 10:48 BST
- Clarification questions by179 days ago1 May 2026, 17:00 BST
- Admission / appointment period ends170 days ago · period end, not a bid countdown11 May 2026, 15:00 BST
- Award decision expected by126 days ago23 Jun 2026, 23:59 BST
- Contract starts57 days ago1 Sept 2026, 00:00 BST
- Assessment summaries sent2 days ago26 Oct 2026
- Latest notice published2 days ago26 Oct 2026, 12:28 GMT
- Today28 Oct 2026
- Standstill endsin 7 days4 Nov 2026, 23:59 GMT
Notice history
11 events · 4 releases on Find a Tender · since 22 May 2025- Pipeline notice published22 May 2025, 10:24 BSTUK1
- Preliminary market engagement notice published12 Aug 2025, 13:02 BSTUK2
- Published value published: £700,000,00012 Aug 2025, 13:02 BST
- Tender notice published13 Apr 2026, 10:48 BSTUK4
- Published value updated to £850,000,00013 Apr 2026, 10:48 BSTwas £700,000,000
- Status changed to active13 Apr 2026, 10:48 BST
- Procurement method changed13 Apr 2026, 10:48 BST
- Deadline published: 11 May 2026, 15:00 BST13 Apr 2026, 10:48 BST
- Contract award notice published26 Oct 2026, 12:28 GMTUK6
- Status changed to complete26 Oct 2026, 12:28 GMT
- Contract signature expected1 Dec 2026, 23:59 GMTscheduled
Routine re-releases (4)
- 2025-05: 1 release · 22 May 2025
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast£850,000,000 is the framework's published maximum, restated by the publisher on 3 award rows. It is one ceiling, not 3 separate sums, and no share per lot is published; those rows read “ceiling above”.
| Awarded to | Value | Date | Status |
|---|---|---|---|
| Lot 1 · Dose Banded Systemic Anti-Cancer Therapy Medicines1 award | |||
| Baxter Healthcare Ltd, ITH Pharma Limited, Lloyds Clinical Limited, Qualasept Ltd t/a Bath ASU, Quantum Pharmaceutical Ltd, Sciensus Pharma Services Ltd1 Dec 2026 – 30 Nov 2034 | ceiling above | 26 Oct 2026standstill to 4 Nov 2026 | Standstill |
| Lot 2 · Patient Specific Systemic Anti-Cancer Therapy Medicines1 award | |||
| Baxter Healthcare Ltd, ITH Pharma Limited, Lloyds Clinical Limited, Qualasept Ltd t/a Bath ASU, Quantum Pharmaceutical Ltd, Sciensus Pharma Services Ltd1 Dec 2026 – 30 Nov 2034 | ceiling above | 26 Oct 2026standstill to 4 Nov 2026 | Standstill |
| Lot 3 · CIVAS (Central Intravenous Additive Service)1 award | |||
| Quantum Pharmaceutical Ltd1 Dec 2026 – 30 Nov 2034 | ceiling above | 26 Oct 2026standstill to 4 Nov 2026 | Standstill |
| Lot 4 · Stock Inventory Management and Supply of Compounded Systemic Anti-Cancer Therapy Medicines1 award | |||
| supplier not published | — | 15 Jun 2026 | Awarded |
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · Dose Banded Systemic Anti-Cancer Therapy Medicines | 6final-stage tenders | 0 | 0 | — |
| 2 · Patient Specific Systemic Anti-Cancer Therapy Medicines | 6final-stage tenders | 0 | 0 | — |
| 3 · CIVAS (Central Intravenous Additive Service) | 1final-stage tenders | 0 | 0 | — |
| 4 · Stock Inventory Management and Supply of Compounded Systemic Anti-Cancer Therapy Medicines | 0final-stage tenders | 0 | 0 | — |
Who bid
- wonLloyds Clinical Ltd · East of England · 1, 2
- wonBaxter Healthcare Ltd · East of England · 1, 2
- wonQuantum Pharmaceutical Limited · North East England · 1, 2, 3
- wonQualasept Limited · South West England · 1, 2
- wonSciensus Pharma Services Limited · Greater London · 1, 2
- wonITH Pharma Ltd · Greater London · 1, 2
Bidders as named on the Procurement Act 2023 award notice. “Won” means the bidder holds an award on this notice.
Contracting authority & participating public bodies
2 public bodies on the noticeOther public bodies
- HealthTrust Europe LLPProcess contact pointProcuring entityOn 11th August 2021, Mid and South Essex NHS Foundation Trust (MSE) published a contract notice for procurement partner services. HealthTrust Europe LLP (HTE) was selected to provide these services under the MSE Framework, including access to HTE's public sector frameworks. HTE is now conducting this procurement exercise as part of its services to the Customers under the MSE Framework.
Framework contractors & participating bidders
6 commercial parties on the notice- Baxter Healthcare LtdFramework contractor
- ITH Pharma LtdFramework contractor
- Lloyds Clinical LtdFramework contractor
- Qualasept LimitedFramework contractor
- Quantum Pharmaceutical LimitedFramework contractor
- Sciensus Pharma Services LimitedFramework contractor
Official documents & specifications (7)
Official links; attachments are not copiedNotices published for this procedure
- Contract award notice Contract award notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Tender notice Tender notice on Find a Tender
- Preliminary market engagement notice Preliminary market engagement notice on Find a Tender
- Pipeline notice Pipeline notice on Find a Tender